New Injectable HIV Prevention Drug Promises Global Revolution

The U.S. Food and Drug Administration (FDA) has approved lenacapavir, the first long-acting injectable formulation for HIV Pre-Exposure Prophylaxis (PrEP). According to brasilemfolhas.com.br, the medication is administered via subcutaneous injection every six months, offering a high-efficacy alternative to daily oral pills for preventing HIV infections.

Lenacapavir functions as a capsid inhibitor. Clinical studies cited by brasilemfolhas.com.br indicate the drug achieved 100% success in preventing new infections within specific study groups. This delivery method aims to resolve adherence issues common with traditional PrEP, where users may struggle to maintain a daily medication schedule.

The shift to a semiannual injection is particularly significant for vulnerable populations. In Brazil, the Unified Health System (SUS) has provided free PrEP since 2018, but only in a daily oral format. Data from the Brazilian Ministry of Health, as reported by brasilemfolhas.com.br, show that many users abandon the daily treatment, which reduces the overall effectiveness of the prevention strategy.

Despite the clinical efficacy, the rollout of lenacapavir faces substantial economic and regulatory hurdles in several regions.

Pricing and Global Access Barriers

A significant gap exists between the cost of producing lenacapavir and its market price. According to brasilemfolhas.com.br, the estimated production cost is between $25 and $46 per year. However, the current price in the United States exceeds $28,000, leading to international pressure for more affordable pricing models.

Gilead Sciences, the pharmaceutical company responsible for the drug, has entered licensing agreements with 17 generic manufacturers to supply low-income countries. However, brasilemfolhas.com.br reports that Brazil, Argentina, and South Africa were excluded from these agreements. This exclusion has raised concerns that the innovation may remain restricted to wealthy nations.

Regulatory Status in Brazil

Lenacapavir is not yet available in Brazil. According to brasilemfolhas.com.br, the drug has not received approval from Anvisa, the Brazilian health regulatory agency. Without this approval, the National Commission for the Incorporation of Technologies (Conitec) cannot evaluate the drug for potential inclusion in the SUS public health system.

The current lack of regulatory approval, combined with the pricing disputes and the absence of generic licensing for the region, creates a barrier for the Brazilian government to integrate the injectable PrEP into its public health infrastructure.